A comparison of the survival benefits of transarterial chemoembolization and conservative treatment in patients with primary hepatic carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-14005432

Enrollment

Unknown

Registered

2014-10-09

Start date

2002-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatic carcinoma

Interventions

TACE group :TACE

conservative group :conservative treatment

Eligibility

Sex/Gender

All

Age

18 Years to 94 Years

Inclusion criteria

Inclusion criteria: (1) All patients were diagnosed to have PHC with or without metastasis to the lymph nodes or other organs; (2) all patients did not have primary malignant tumor in other organs; and (3) all patients have not undergone any other operation, liver transplantation, local ablation, and chemotherapy or any form of biological and immunological therapies.

Exclusion criteria

Exclusion criteria: The patients who have undergone any other operation, liver transplantation, local ablation, and chemotherapy or any form of biological and immunological therapies.

Design outcomes

Primary

Measure	Time frame
survival period;survival rate;	—

Secondary

Measure	Time frame
survival predictor;	—

Countries

China

Contacts

Public ContactSheng-Mian Li

shengmianli2013@163.com+86 0311-86095342

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026